Stock Monitor: Aptevo Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARWR as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it presented new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3 and ARO-APOC3 at the Vascular Discovery: From Genes to Medicine? Scientific Sessions 2018, San Francisco, May 10-12, 2018, a symposium organized by the American Heart Association. Arrowhead intends to file clinical trial applications (CTA) for ARO-ANG3 and ARO-APOC3 before the end of 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Aptevo Therapeutics Inc. (NASDAQ: APVO), which also belongs to the Healthcare sector as the Company Arrowhead Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=APVO

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Arrowhead Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ARWR

Arrowhead to Present Additional Results from Ongoing Preclinical Studies of ARO-APOC3 & ARO-ANG3 at Scientific Conferences Later in 2018

Bruce Given, M.D., Chief Operating Officer and Head of R&D at Arrowhead, stated that the Company has a growing body of compelling preclinical data in a diverse set of models for ARO-APOC3 and ARO-ANG3, the newest candidates in Arrowhead's cardiometabolic pipeline that leverage its Targeted RNAi Molecule (TRiMTM) platform.

Bruce added that Arrowhead intends to present additional results from ongoing preclinical studies of ARO-APOC3 and ARO-ANG3 at scientific conferences later this year.

Details of the Presentation

In the presentation, the recent progress achieved using RNA interference as a therapeutic modality for the development of new drugs to treat cardiovascular diseases was discussed. The new preclinical data presented on ARO-APOC3 and ARO-ANG3 included the following:

  • A single 2 mg/kg dose of ARO-APOC3 in ApoC3 transgenic mice led to the observations: Serum ApoC3 levels were reduced by around 90%, maximum knockdown was sustained for over three weeks, the lipid profiles improved with large reductions in serum triglycerides and cholesterol, and large increases in HDL.

  • In dose ranging studies of ARO-ANG3 in wild type mice, reductions in serum ANGPTL3 and liver mRNA were similar, indicating that the observed knockdown of serum ANGPTL3 is a direct result of the expected RNAi effect.

  • The LDL receptor knock-out (LDLr-/-) mice, leptin receptor defective db/db mice and diet-induced obese (DIO) mice disease models were also interrogated.

  • A single 3 mg/kg dose in LDLr-/- mice and in db/db mice led to a maximum reduction of ANGPTL3 of 98%, and substantial decreases in serum triglycerides and LDL.

  • A single 3 mg/kg dose in DIO mice led to a maximum reduction of ANGPTL3 of 99.7%, and approximately 50-60% reductions in serum triglycerides and LDL.

About ARO-ANG3 and ARO-APOC3

ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum, and liver triglyceride and has genetic validation as a novel target for cardiovascular disease.

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

About Arrowhead Pharmaceuticals, Inc.

Founded in 2004 and headquartered in Pasadena, California, Arrowhead Pharma develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

Stock Performance Snapshot

May 14, 2018 - At Monday's closing bell, Arrowhead Pharma's stock dropped 4.66%, ending the trading session at $9.42.

Volume traded for the day: 3.07 million shares, which was above the 3-month average volume of 1.49 million shares.

Stock performance in the last month ? up 30.47%; previous three-month period ? up 77.40%; past twelve-month period ? up 454.12%; and year-to-date - up 155.98%

After yesterday's close, Arrowhead Pharma's market cap was at $744.75 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.7% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors